NCHR Author

Cancer Prevention and Treatment Funds’ Comments On USPSTF Draft Recommendation Statement for Breast Cancer: Medication Use to Reduce Risk

February 11, 2019. CPTF comments on the USPSTF breast cancer medications such as tamoxifen and raloxifene that are used to reduce risk in patients.

The USPSTF Draft Recommendations on Medication Use to Prevent Breast Cancer: Comments by Women’s Health Experts

February 11, 2019. NCHR writes on behalf of five nonprofit health organizations that have examined issues pertaining to primary prevention of breast cancer for decades and urge the USPSTF to consider revising their current recommendations on breast cancer risk reducing drugs.

NCHR Comments on USPSTF’s Draft Research Plan for Colorectal Cancer: Screening

January 30, 2019. We strongly support the USPSTF’s efforts to update recommendations for different types of colorectal cancer screening for different demographic subgroups, as well as their broader efforts to improve the health of all Americans by making evidence-based recommendations about clinical preventive services.

Testimony at FDA on Romosozumab to Help Manage Postmenopausal Osteoporosis

NCHR testifies against drug Romosozumab for having cardiac safety issues.

Testimony at FDA on Sotagliflozin to Help Manage Type 1 Diabetes

January 17, 2019. Just providing new treatment options is not enough. New treatments must provide a real tangible benefit for patients without too much risk.